Results 91 to 100 of about 58,845 (265)

Measurement and management of adult blood pressure in the peri‐operative period: updated guidelines from the Association of Anaesthetists and the British and Irish Hypertension Society

Anaesthesia, EarlyView.
Summary Introduction Maintaining stable blood pressure during surgery is a key responsibility of anaesthetists. Peri‐operative omission and reintroduction of antihypertensive drugs, general anaesthesia, neuraxial and regional techniques can all cause significant fluctuations in blood pressure, particularly in patients with hypertension. Since the first
Terry McCormack, Alex Wickham, Sinéad T. J. McDonagh, Matthew D. Wiles, Luca Faconti, Rachael Brooks, Simon G. Anderson, Andrew Hartle   +7 more
wiley   +1 more source

Relationship between antihypertensive medications and cognitive impairment: Part II. Review of Physiology and animal studies [PDF]

, 2016
Purpose of Review There is an established association between hypertension and increased risk of poor cognitive performance and dementia including Alzheimer’s disease; however, associations between antihypertensive medications (AHM) and dementia risk are
Carlson, MC, Peters, J, Peters, R, Schuchman, M, Yasar, S   +4 more
core   +1 more source

Network medicine and systems pharmacology approaches to predicting adverse drug effects

British Journal of Pharmacology, EarlyView.
Identifying and understanding the relationships between drug intake and adverse effects that can occur due to inadvertent molecular interactions between drugs and targets is a difficult task, especially considering the numerous variables that can influence the onset of such events.
Alessio Funari, Giulia Fiscon, Paola Paci   +2 more
wiley   +1 more source

A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs

British Journal of Pharmacology, EarlyView.
Background The activity of CYP2C9, an important drug metabolism enzyme, is subject to the impact of genetic polymorphism. The single nucleotide polymorphism *3 is significantly associated with the increased exposure of CYP2C9 substrates. In addition, metabolic enzyme inhibitors such as fluconazole may also increase the drug exposure of CYP2C9 ...
Shen Cheng, Darcy R. Flora, Mutaz M. Jaber, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy   +5 more
wiley   +1 more source

Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

PLoS ONE, 2019
There is no cure or beneficial management option for Limb-Girdle muscular dystrophy (MD) type 2B (LGMD2B). Losartan, a blood pressure (BP) lowering angiotensin II (AngII) receptor type 1 (ATR1) blocker (ARB) with unique anti-transforming growth factor-β (
Zoe White, Nadia Milad, Arash Y Tehrani, William Wei-Han Chen, Graham Donen, Stephanie L Sellers, Pascal Bernatchez   +6 more
doaj   +1 more source

Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department [PDF]

, 2020
As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise.
Brown, Cortlyn, Coralic, Zlatan, Noble, Jeanne   +2 more
core  

Cryptococcid Sweet Syndrome in the Setting of Hydralazine‐Induced ANCA Vasculitis: A Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Acute febrile neutrophilic dermatosis, also known as Sweet syndrome, is an inflammatory skin condition characterized by the rapid onset of painful, erythematous plaques or nodules with neutrophilic infiltrate on histology. Rarely, acellular bodies surrounded by vacuolated spaces have been noted within the neutrophilic infiltrate, mimicking ...
Jenna Vroman, Pelin Sagut, Kathryn Lynam, Amanda Ederle, Laura Winterfield   +4 more
wiley   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources